Install
DocWire News delivers the latest health care news, research, and trends in medicine, giving health care professionals access to the curated content most relevant to their fields.
- 66articles · 30d
- 13+ hour agolatest article
- Aug 14, 2026earliest in window
- 95%with images
- 265avg words
- Health & Wellness 66
- Medical 63
- Health 61
- Education 2
- Finance & Business 2
- Economy, Business & Finance 1
- Labour 1
- Politics 1
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Endocrine Therapy for ESR1-Mutated Metastatic Breast Cancer
13+ hour, 28+ min ago (216+ words) In the first segment of this roundtable series, the panel discusses the current treatment landscape, how it has evolved with new approvals and data, ongoing trials, and what might be on the horizon for patients with ESR1-mutated disease in the…...
Beyond the First-Line for ESR1-Mutated Disease
13+ hour, 28+ min ago (273+ words) An expert panel moderated by Sara Nunnery, MD, of Tennessee Oncology, convened to discuss how they choose therapy beyond the first-line setting for patients with ESR1-mutated disease. Dr. Nunnery was joined by Nan Chen, MD, of the University of Chicago;…...
Updates in Melanoma From ASCO
2+ day, 8+ hour ago (379+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates in melanoma presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Meredith McKean, MD, MPH: Hi, I am Meredith McKean. I’m a…...
Updates to Merkel Cell Carcinoma From ASCO
2+ day, 8+ hour ago (320+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates to Merkel cell carcinoma (MCC) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. McKean describes updates from the STAMP, ADAM, and…...
Biparatopic HER2 Targeting in Action: Anbenitamab???s Phase 3 Breakthrough
2+ day, 8+ hour ago (38+ words) Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Docwire News Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Shao ZM, et al. Basch E, et al. 2026 American Society of Clinical Oncology Annual Meeting. Abstract LBA660....
The Real Barriers to HER2-Low Breast Cancer Care
2+ day, 8+ hour ago (85+ words) Docwire News The Real Barriers to HER2-Low Breast Cancer Care While HER2 testing rates in breast cancer are already high, Dr. Jessica Paulus, of Ontada, reveals a more subtle challenge: how clinicians interpret and act on those results, particularly in the…...
USP9X: A Potential New Way to Sensitize Tumors to ADC Therapy
2+ day, 8+ hour ago (213+ words) By performing whole‑genome CRISPR screens in heterogeneous co‑cultures, Dr. Kornelia Polyak et al. identified genes that sensitize HER2‑low cells to T‑DXd. In this segment, Dr. Polyak focuses on USP9X and ABCC1, explaining why USP9X stood out as a promising and…...
Five-Year PHERGain Results Validate pCR-Guided Treatment De-Escalation
2+ day, 8+ hour ago (136+ words) Docwire News Five-Year PHERGain Results Validate pCR-Guided Treatment De-Escalation According to Dr. Antonio Llombart-Cussac, the 5-year PHERGain analysis confirms the long-term safety and effectiveness of a chemotherapy-sparing, response-guided approach in HER2-positive breast cancer, with approximately 91% invasive disease-free survival across the…...
PHERGain-2: Targeted Therapy Alone Achieves Strong Responses in Early HER2+ Breast Cancer
2+ day, 8+ hour ago (144+ words) Docwire News PHERGain-2: Targeted Therapy Alone Achieves Strong Responses in Early HER2+ Breast Cancer As explained onsite from ESMO Breast Cancer 2026 by Dr. Antonio Llombart-Cussac, PHERGain-2 builds on prior de-escalation research to evaluate a chemotherapy-free, pCR-guided strategy in early HER2-positive breast…...
Dato-DXd vs Chemotherapy: What Does TROPION-Breast02 Mean for Practice?
2+ day, 8+ hour ago (721+ words) The following transcript has been edited for clarity. Dr. Nunnery: Hi everyone. I’m Sara Nunnery. I’m a breast medical oncologist and the director of breast cancer research at Tennessee Oncology based in Nashville, Tennessee. Really happy to be here to…...